Table 2.
List of drugs used in T2DM
S. no | Plant/drug | Extract/compound | Mechanism of action | Organ function | Findings | Recommended/not recommended | Reference |
---|---|---|---|---|---|---|---|
1 | Moringa oleifera | Moringa seeds | Lessening the expression of iNOS, IL-1β, NO, TNF-α | Liver | ↓plasma glucose levels, HbA1c | Recommended | [113] |
2 | Garcinia macrophylla | 5,7,4′,5″,7″,3‴,4‴-heptahydroxyflavanone [3–6″] flavones | Antibacterial, antioxidant, and anti-T2DM | - | ↓ glucose level | Recommended | [114] |
3 | Albendazole lansoprazole | - | Activation of AMPK and PPAR pathways and incretin-like effect | - |
↑ glucose, HbA1c, triglyceride, LDL, leptin ↓insulin and HOMA-β |
Recommended | [115] |
4 | Remogliflozin etabonate (100 mg and 250 mg) | - | SGLT2 inhibition improves urinary glucose excretion thereby decreases blood glucose levels | ↓ glucose levels | Recommended | [116] | |
5 | Metformin hydrochloride | - | Lessens intestinal glucose absorption, declines hepatic glucose production, increases insulin sensitivity | Liver | ↓HbA1c levels, FBG, and weight loss | Recommended | [117] |
6 | Remogliflozin metformin teneligliptin | - | - | - | ↓glucose levels, weight | Recommended | [118] |
7 | Rhizoma coptidis | Berberine and polyphenols | Improves β cell dysfunction | Liver adipose tissues |
↓IL-6, TNFα ↑islet cell viability |
Recommended | [119] |
8 | Alkaline and flavone category compounds | MAPK1, STAT3, INSR, and 38 signalling pathways | - | Insulin resistance | Recommended | [120] | |
9 | Morus alba | Chlorogenic acid, isoquercitrin, and quercitrin | - | - | Glucose absorption, insulin secretion, antioxidant, anti-inflammatory, antihyperglycemic, and antihyperlipidemic activities, declined obesity | Recommended | [121] |
10 | Zingiber officinale | - | - | Heart |
↑diastole function and blood pressure ↓ HbA1c, triglycerides |
Recommended | [122] |
11 | Glargine/lixisenatide | - | GLP-1 RA, control postprandial glucose improved β-cell function | - |
↓ HbA1c, weight gain ↓ glucose levels |
Recommended | [123] |
12 | Gegen Qinlian decoction berberine | - | Proinflammatory cytokines Nfkb1, Stat1, and Ifnrg1 | Pancreas |
Enriched gut microflora ↓ glucose levels |
- | [124] |
13 | Gegen Qinlian decoction (meta-analysis study) | - | - | Pancreas |
↓ glucose levels ↑islet function ↓insulin resistance and sensitivity indexes |
A need for clinical prognosis and islet function | [125] |
14 | Huanglian Jiedu decoction | Decoction has Huanglian, Huangqin, Huangbo, and Zhizi mixture | Targets AKT1, IL-6, FOS, VEGFA, CASP3 | Pancreas | ↓ glucose levels, HbA1c | Recommended | [126] |
15 | - | Enhance GLUT4, INSR, MAPK1 | - | Improve in fasting glucose level, lipid level, insulin sensitivity index | Recommended | [127] | |
16 | Nigella sativa (meta-analysis study) | Thymol, thymohydroquinone, dithymoquinone, nigellone, alpha-hederin, flavonoids, and fatty acids | Antidiabetic, antioxidant, anticancer, hypolipidemic, and anti-inflammatory properties | - | ↓ HbA1c, glucose level, insulin resistance | Recommended | [128] |
17 | Metformin with Chinese traditional medicine | - | - | - | Lessened the hyperglycemia, altered gut microflora, improved insulin resistance | Recommended | [129] |
18 | GLP-1RAs and oral anti-diabetic drugs (meta-analysis) | - | - | Heart | Improvement in left ventricular diastolic function | Recommended | [130] |
19 | GLP-1 RA and SGLT-2i (meta-analysis) | - | - | Pancreas | 5 studies—GLP-1 RA showed decreasing effect in cardiovascular complications, glucose reduction | Recommended | [131] |
20 | Metformin and DDP-4 inhibitors | - | AMPK pathway activation, NFK-β, and mTOR suppression | - | Adverse outcome from COVID-19 | Not recommended | [132] |
21 | Statin, fibrates, and its combination | - | - | - | ↓lipid levels | Recommended | [133] |
22 | Incretin, DDP-4 inhibitors, and GLP-1 RA | - | - | - | ↓ HbA1c | Recommended | [134] |
23 | Anti-hyperglycaemic therapies (GLP-1 RA and SGLT2i) | - | - | - | No change in HbA1c levels | Recommended | [135] |
24 | Metformin (meta-analysis) | - | - | - |
↓ HbA1c ↓ glucose levels |
Recommended | [136] |
25 | Aspirin and statin | - | - | Heart | ↓cardiovascular complications in T2DM | Recommended | [133] |
26 | Tofogliflozin with DDP-4 inhibitors | - | - | Pancreas | ↓postprandial glucose | Recommended | [137] |
27 | Momordica charantia | - | - | Pancreas |
↑insulin secretion ↓glucose uptake |
Recommended | [138, 139] |
28 | Metformin | - | - | Pancreas | ↑epigenetic markers | Recommended for diagnosis | [140] |
29 | Chenpi | 5-OH PMFs |
Antidigestive and anti-inflammatory AMPK activation |
↓hepatic steatosis ↓glucose levels |
Recommended | [141] | |
30 | Aloe vera | - | - | - | ↓glucose levels | Recommended | [142] |
31 | Berberine | - | - | Pancreas |
↓ HbA1c levels ↓ cholesterol and triglyceride ↑insulin secretion |
Recommended | [143] |
32 | Pueraria lobata (meta-analysis) | - | - | Pancreas | Anti-diabetic activity | Recommended | [144] |
33 | SGLT-2i and GLP-1 RA | - | - | Heart | ↓cardiorenal problems, stroke | Recommended | [145] |
34 | - | - | Heart kidney |
↓renal risk No significance in cardio condition |
Recommended | [146, 147] | |
35 | Sulfonylureas, DPP-4 inhibitors, meglitinides | - | - | Heart | ↑myocardium infection | Recommended | [148] |
36 | Acupuncture with Chinese herbal medicine (meta-analysis) | - |
↓glucose levels ↑ insulin sensitivity and resistance |
Recommended | [149] | ||
37 | Ipragliflozin (meta-analysis) | - | - | - |
↑ genital infection No significance in glucose level |
Not recommended | [150] |
38 | Ginseng supplementation | - | - | - |
↑fasting glucose, postprandial insulin, and HOMA-IR Lipid levels were altered |
Recommended | [151] |
39 |
Shenqi Jiangtang Granules Baihu Jia Renshen Decoction Tianqi Jiangtang Capsule (meta-analysis) |
- | - | Pancreas | ↓hypoglycemia levels | Recommended | [152–154] |
40 | Chinese tradition medicine vs. Western medicine (meta-analysis) | - | - | Pancreas | Traditional medicine showed enhanced insulin sensitivity, decreasing body weight, protects from β cells | Recommended | [155] |
41 | Cotadutide (meta-analysis) | - | - | Pancreas | ↓glucose levels, HbA1c and body weight | Recommended | [156] |
42 | SGD | - | Influences PI3K-Akt, AMPK, and PPAR | Pancreas | ↓ glucose levels and lipid levels ↓ | Recommended | [157] |
43 | Sancai powder | - | - | Pancreas | ↓glucose levels, HbA1c, lipid levels | Recommended | [117] |
44 | Zhimu-Huangbai herb pair | - | - | Pancreas | ↓glucose levels | Recommended | [158] |
45 | Naoxintong capsule | - | Arachidonic acid metabolism, fatty acid β-oxidation, and glycerophospholipid metabolism | Pancreas | ↓hyperlipidemia, hyperglycemia, myocardial infarction, insulin resistance | Recommended | [159, p. 20] |
46 | Pioglitazone and canagliflozin | - | - | - | ↓ glucose levels, lipid levels, HbA1c | Recommended | [160] |
47 | Canagliflozin | - | - | Kidney | ↑ renal oxygen in T2DM | Recommended | [161] |
48 | Pine bark extract | - | - | Pancreas | ↓ HbA1c, VCAM-1, cholesterol levels, UACR | Recommended | [162] |
49 | Jinlida granules | - | - | Pancreas | ↓ HbA1c and glucose levels | Recommended | [163] |
iNOS, inducible nitric oxide synthase; IL-1β, interleukin-1 beta; NO, nitric oxide; TNF-α, tumour necrosis factor alpha; HbA1c, glycated haemoglobin; T2DM, type 2 diabetes mellitus; LDL, low density cholesterol; HOMA-β, homeostasis model assessment of β-cell function; AMPK, adenosine 5′ -monophosphate activated protein kinase; PPAR, peroxisome proliferator-activated receptor; SGLT-2, sodium glucose co-transporter-2; SGLT-2i, sodium-glucose cotransporter-2 inhibitors; FBG, fasting blood glucose; GLP-1 RA, glucagon-like peptide 1 receptor agonists; DDP-4, dipeptidyl peptidase-4 inhibitors; NFK-β, nuclear factor kappa B; mTOR, mammalian target of rapamycin; COVID-19, coronavirus disease-19; 5-OH PMFs, 5-demethylated poly methoxy flavones; HOMA-IR, homeostatic model assessment of insulin resistance; SGD, Shengmai-Yin and Ganmai dazao decoction; VCAM-1, vascular cell adhesion molecule 1; UACR, urinary albumin-to-creatinine ratio; PPAR, peroxisome proliferator-activated receptors; P13K-Akt, phosphatidylinositol 3-kinase-protein kinase B; GLUT4, glucose transporter type 4; INSR, insulin receptor; MAPK1, mitogen-activated protein kinase 1; IL-6, interleukin-6; FOS, Fos proto-oncogene; AP-1, transcription factor subunit; VEGFA, vascular endothelial growth factor A; CASP3, caspase 3; Stat1, signal transducer and activator of transcription 1; Ifngr1, interferon gamma receptor 1; STAT3, signal transducer and activator of transcription 3